Hirst R C, McCullagh K J A, Davies K E
MRC Functional Genetics Unit, Department of Human Anatomy and Genetics, South Parks Road, Oxford, UK.
Acta Myol. 2005 Dec;24(3):209-16.
Duchenne Muscular Dystrophy (DMD) is a devastating, progressive muscle wasting disease for which there is currently no effective treatment. DMD is caused by mutations in the dystrophin gene many of which result in the absence of the large cytoskeletal protein dystrophin at the sarcolemma. Over-expression of utrophin, the autosomal paralogue of dystrophin, as a transgene in the mdx mouse (the mouse model of DMD) has demonstrated that utrophin can prevent the muscle pathology. Thus, up-regulation of utrophin in DMD muscle is a potential therapy for DMD. In this review we discuss recent advances in our understanding of the regulatory pathways controlling utrophin expression and the various approaches that have been applied to increasing the level of utrophin in the mdx mouse. These results are very encouraging and suggest that pharmacological up-regulation of utrophin may well be a feasible approach to therapy for DMD.
杜氏肌营养不良症(DMD)是一种毁灭性的进行性肌肉萎缩疾病,目前尚无有效治疗方法。DMD由肌营养不良蛋白基因突变引起,其中许多突变导致肌膜上缺乏大型细胞骨架蛋白肌营养不良蛋白。作为肌营养不良蛋白的常染色体旁系同源物,抗肌萎缩蛋白聚糖在mdx小鼠(DMD的小鼠模型)中作为转基因过度表达,已证明抗肌萎缩蛋白聚糖可以预防肌肉病变。因此,上调DMD肌肉中的抗肌萎缩蛋白聚糖是DMD的一种潜在治疗方法。在这篇综述中,我们讨论了我们对控制抗肌萎缩蛋白聚糖表达的调节途径的最新理解进展,以及为提高mdx小鼠中抗肌萎缩蛋白聚糖水平而应用的各种方法。这些结果非常令人鼓舞,表明抗肌萎缩蛋白聚糖的药理学上调很可能是一种可行的DMD治疗方法。